Search

Your search keyword '"Jong Ho Cho"' showing total 22 results
Start Over Author "Jong Ho Cho" Journal journal of thoracic oncology
22 results on '"Jong Ho Cho"'

2. Recommended Change in the N Descriptor Proposed by the International Association for the Study of Lung Cancer: A Validation Study

Author

Jhingook Kim, Byung Jo Park, Tae Ho Kim, Hong Kwan Kim, Sumin Shin, Jae Ill Zo, Young Mog Shim, Jong Ho Cho, and Yong Soo Choi

Subjects
Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Validation study, Lung Neoplasms, Disease, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, Lung cancer, Prospective cohort study, Pathological, Societies, Medical, Survival analysis, Neoplasm Staging, Retrospective Studies, Proportional hazards model, business.industry, International Agencies, Reproducibility of Results, Middle Aged, Prognosis, medicine.disease, Survival Rate, 030104 developmental biology, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, Cohort, Lymph Node Excision, Female, Lymph Nodes, business
Abstract

Introduction The International Association for the Study of Lung Cancer recently proposed a new N descriptor by combining the location of metastatic lymph nodes (LNs), nN (single-station versus multiple-station), and absence versus presence of skip metastasis as pN1a, pN1b, pN2a1, pN2a2 and pN2b. This study aimed to evaluate the discriminatory ability and prognostic performance of the proposed N descriptor in a large independent NSCLC cohort. Methods We analyzed 1228 patients who underwent major pulmonary resection for pathological N1 or N2 NSCLC between 2004 and 2014. Survival analysis using the Cox proportional hazard model was performed to assess the prognostic significance of the N descriptor. Results From 2004 to 2014, a total of 7437 patients were operated on for NSCLC. Patients pathologically confirmed as having N1 (n = 732) or N2 (n = 496) disease after surgery were included. The median total number of dissected LNs was 24 (range 10–83), and the median number of involved LNs was 2 (range 1–40). The 5-year overall survival rates were 62.6%, 57.0%, 64.7%, 48.4%, and 42.8% for stages N1a, N1b, N2a1, N2a2, and N2b, respectively. Analysis of overall and recurrence-free survival revealed that N2a1 is not sufficiently distinguished from N1a and N1b. In terms of overall survival, N1b is not sufficiently distinguished from N2a2. Conclusion On the basis of the N descriptor proposed by the International Association for the Study of Lung Cancer, some of the prognostic implications of the five groups overlapped. It would be better to classify similar prognostic groups into three or four groups to divide the group. A large-scale prospective study is needed to validate these N descriptors.

Published
2019

3. MA08.03 Adjuvant Pembrolizumab in N2 Positive NSCLC Treated with Concurrent Chemoradiotherapy Followed by Surgery: Phase II, Prospective Study

Author

S.H. Park, Joonghyun Ahn, Hyun Ae Jung, Y.S. Choi, K. Park, J.I. Zo, Jong Ho Cho, Young Mog Shim, S.J. Lee, M-J. Ahn, J. Kim, Jong-Mu Sun, and H.K. Kim

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine.medical_treatment, medicine, Pembrolizumab, business, Prospective cohort study, Adjuvant, Concurrent chemoradiotherapy
Published
2019

6. MA06.03 Recurrence Dynamics after Trimodality Therapy (Neoadjuvant Chemoradiotherapy and Surgery) in Stage IIIa(N2) Lung Cancer

Author

Young Mog Shim, Hong Kwan Kim, Sumin Shin, Jin Seok Ahn, Yong Chan Ahn, Hong Ryull Pyo, Keunchil Park, Jung Hee Lee, Byung Jo Park, Myung-Ju Ahn, Jhingook Kim, Jae Ill Zo, Jong Ho Cho, and Yong Soo Choi

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Stage IIIa, business, Lung cancer, medicine.disease, Neoadjuvant chemoradiotherapy
Published
2017

7. P2.04-001 A Comparative Analysis of Long-Term Outcome of Thymoma between Video-Assisted Surgery and Open Resection from Multi-Center Study Data

Author

Su Kyung Hwang, Chang Hyun Kang, Jong Ho Cho, Chang Young Lee, and Dong Kwan Kim

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Thymoma, business.industry, Video-Assisted Surgery, medicine.disease, Outcome (game theory), Surgery, Term (time), Oncology, Multi center study, Open Resection, medicine, business
Published
2017

9. P1.05-048 Effect of Adjuvant Chemotherapy on the Patterns and Dynamics of Recurrences in Resected Stage II(N1) Lung Adenocarcinoma

Author

Jin Seok Ahn, Jong Ho Cho, Byung Jo Park, Sumin Shin, Hong Kwan Kim, Yong Soo Choi, Jung Hee Lee, Jhingook Kim, Myung-Ju Ahn, Keunchil Park, Young Mog Shim, and Jae Ill Zo

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung, business.industry, Adjuvant chemotherapy, Stage ii, medicine.disease, medicine.anatomical_structure, Internal medicine, Medicine, Adenocarcinoma, business
Published
2017

10. OA10.05 An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09)

Author

Joonghyun Ahn, Suk-Koo Lee, Yoon Hee Choi, Ho Jung An, Eun Joo Kang, Keon Uk Park, Kwang Bo Park, Jong-Mu Sun, Hyun Woo Lee, M-J. Ahn, Kwang Hyun Kim, and Jong Ho Cho

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Egfr mutation, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Osimertinib, Open label, business
Published
2018

11. P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients with Lung Cancer

Author

Jong Ho Cho, Yoo-Duk Choi, M-J. Ahn, Kyu-Sung Park, Joonghyun Ahn, Jong-Mu Sun, S.H. Lee, and J. Hyeon

Subjects
Pulmonary and Respiratory Medicine, biology, business.industry, Immune checkpoint inhibitors, Anti pd 1, medicine.disease, Oncology, PD-L1, biology.protein, Cancer research, Medicine, Immunohistochemistry, In patient, business, Lung cancer
Published
2018

14. P3.01-023 First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice

Author

M-J. Ahn, Joonghyun Ahn, Seungjin Lim, Hyun-Moo Lee, Kyu-Sung Park, Song Ee Park, Younsoo Kim, Jong-Mu Sun, H.K. Kim, S.J. Lee, and Jong Ho Cho

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, First line, Afatinib, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Non small cell, business, Lung cancer, medicine.drug
Published
2017

17. P3.02-011 A Prospective Study of Serial Circulating Tumor DNA Assessment in Detecting Recurrence of Resected Early-stage Lung Cancer

Author

J. Kim, J. Odegaard, Young Mog Shim, J.I. Zo, Jong Ho Cho, Jinseon Lee, S.J. Lee, S. Mortimer, H.K. Kim, and Y.S. Choi

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Pathology, business.industry, medicine.disease, Circulating tumor DNA, Internal medicine, medicine, Stage (cooking), Lung cancer, Prospective cohort study, business
Published
2017

18. P3.08-006 Treatment Response and Survival Outcomes Are Associated with Histologic Type in Non-Small Cell Lung Cancer Treated with Trimodal Treatment

Author

Y.S. Choi, Joonghyun Ahn, Young Mog Shim, J. Kim, Yong Chan Ahn, Sun Hye Shin, Hongryull Pyo, M-J. Ahn, J.I. Zo, H.K. Kim, Joungho Han, S.J. Lee, Jong Ho Cho, Jong-Mu Sun, J.M. Noh, and K. Park

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Pathology, Treatment response, business.industry, medicine.disease, Internal medicine, medicine, Histologic type, Non small cell, Lung cancer, business
Published
2017

19. P2.07-025 Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer

Author

Yun-Soon Kim, Kyu-Sung Park, Sung-Nam Lim, Joonghyun Ahn, M-J. Ahn, Hoon-Kyo Kim, Song Ee Park, Jong Ho Cho, Jong-Mu Sun, Hyun-Moo Lee, and S.H. Lee

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Chemotherapy, biology, business.industry, medicine.medical_treatment, Antitumor response, medicine.disease, PD-L1, Internal medicine, medicine, biology.protein, In patient, Non small cell, Lung cancer, business
Published
2017

20. P2.02-044 Impact of N2 Extent and Nodal Response on Survival after Trimodal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer

Author

Hong Kwan Kim, Jhingook Kim, Jong Ho Cho, Joungho Han, Jin Seok Ahn, Yong Chan Ahn, Myung-Ju Ahn, Keunchil Park, Hong Ryull Pyo, Jae Ill Zo, Yong Soo Choi, Young Mog Shim, and Hojoong Kim

Subjects
Pulmonary and Respiratory Medicine, Oncology, Prognostic factor, medicine.medical_specialty, business.industry, medicine.disease, Internal medicine, Medicine, Non small cell, Stage IIIa, business, NODAL, Lung cancer
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results